Table 4.

Treatment efficacy and adherence to therapy

	PWID group	Control group	p
SVR 12	99 (98%)	172 (98%)	N. S.
Lost to follow-up	2 (2.0%)	1 (0.6%)
Relapse	0 (0%)	4 (1.4%)
SVR 24	89 (88.1%)	163 (92.1%)	N. S.
Lost to follow-up	10 (9.9%)	5 (2.8%)
Relapse	1 (1%)	9 (5.1%)
Reinfection	1 (1%)	0 (0%)
SVR 12 according to adherence			N. S.
100% adherent	69 (100%)	153 (95.6%)
Non-100% adherent	30 (93.8%)	15 (88.2%)
Treatment termination on time	99 (98%)	169 (95.5%)	N. S.
Premature treatment termination	0 (0%)	1 (0.6%)	N. S.
Postponed treatment termination	2 (2.0%)	7 (4.0%)	N. S.
Delay (days)
Patient 1	3
Patient 2	3
Patient 3		2
Patient 4		1
Patient 5		1
Patient 6		1
Patient 7		7
Patient 8		2
Patient 9		2
Missed doses (no. of patients)
1 dose	0	3	N. S.
2 doses	0	3
3 doses	2	0
7 doses	0	1
Postponed visits (no. of patients)	29 (28.7%)	7 (4.0%)	< 0.001
1 visit	17	7
2 visits	8	0
3 visits	4	0
Missed visits (no. of patients)	13 (12.9%)	6 (3.4%)	0.006
1 visit	11	6
2 visits	2	0
Lack of medication (no. of patients)	1 (1%)	2 (1.1%)	N. S.
Patient 1 (missed doses)	3
Patient 2 (missed doses)		2
Patient 3 (missed doses)		2
Missed visit 12 weeks post-treatment (SVR 12)	2 (2%)	1 (0.6%)	N. S.
Missed visit 24 weeks post-treatment (SVR 24)	11 (10.9%)	2 (1.1%)	0.004

P value of < 0.05 was considered statistically significant and the results are displayed in bold

PWID people who inject drugs group, SVR sustained virological response